Dr. Reddy's ADR Stabilises but the Damage Is Done

Dr. Reddy's Laboratories reports again on July 24 — but for the ADR, the real verdict is already in the price.

The stock bounced 3.7% on July 23 to $11.80, a partial recovery after the 9.4% one-day collapse that followed the Q1 print on July 22. The one-month decline still reaches 15.2%, and the week remains down 7.1%. That single-session rebound has loosened availability somewhat — it recovered to 60% on July 22 after tightening back to 45% the prior session, a sharp reversal from the mid-60s range that had prevailed before the earnings drop. Cost to borrow has eased considerably from its late-June peak above 8.6% to 1.45%, reflecting less urgent demand for shorts even as the borrow market remains tighter than it was two months ago. The ORTEX short score is holding near 58, moderately elevated but no longer drifting lower as it was in early July.

Options traders have grown more cautious since the pre-earnings setup. The put/call ratio has risen to 0.61, above its 20-day average of 0.43 — a z-score of 1.47, the most defensive positioning has been in weeks. That compares to a PCR of just 0.48 heading into the July 22 print, which had already been flagged as above-average. The acceleration since suggests the sell-off has prompted fresh demand for downside protection rather than relief buying.

The fundamental case remains contested. Generic competition has intensified in key markets, weighing on margins even as revenue growth stays steady. The EV/EBITDA multiple has compressed to 12.3x and the P/E to 19x — both down meaningfully over the past month, reflecting the stock's re-rating lower. Bulls point to API segment expansion and emerging market growth as long-term levers. The EPS 12-month forward growth score ranks in the 63rd percentile, which is constructive, but EPS surprise ranks in just the 11th percentile — the company has a recent history of missing estimates, which amplifies the risk around any fresh disclosure.

The July 24 event is therefore less about the headline earnings number — those were already delivered on July 22 — and more about whether management's commentary on pricing pressure and the pace of generic erosion is enough to arrest a stock that has now lost 15% in a month against a sector that has not followed it lower.